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Clinical Commentary
How Detrimental Is Chronic Use of Bronchodilators in 
Asthma and Chronic Obstructive Pulmonary Disease?
C. P. VAN SCHAYCK, S. G. M. CLOOSTERMAN, I. D. HOFLAND, C. L. A. VAN HERWAARDEN, 
and C. v a n  WEEL
Department of General Practice, Nijmegen University, Nijmegen, and University Lung Centre, Dekkerswald, the Netherlands
Recently, interest in the possibly detrimental effects of chronic 
bronchodllator use for treating asthma and chronic obstructive 
pulmonary disease (COPD) has increased. It started with the ob­
servation that there was an association between the use of (J-ag- 
onists and death from asthma (1-6). The concern increased when 
clinical trials reported increased bronchial hyperresponsiveness 
(7-9), increased decline in lung function (10), or worsened overall 
control of asthma during continuous use of (3-agonists (11). Very 
recently, it was observed that 3-agonists might even cause toler­
ance to the protective effect against provocative stimuli such as 
methacholine (12,13), AMP (13), and allergen (14). All these obser­
vations have caused considerable concern among doctors and pa­
tients. News media have paid a lot of attention to the possibly 
detrimental effects of bronchodilators. There are many examples 
of patients who refuse to use their medication any more after read­
ing frightening headlines. Therefore, it seems worth questioning 
how detrimental the chronic use of bronchodilators really is. How 
firm is the evidence for deleterious effects of these drugs? A care­
ful review of the literature does not provide firm evidence that bron­
chodilators cause increased asthma morbidity or mortality.
From a meta-analysis of all available studies assessing the as­
sociation between p-agonist use and death from asthma, Mullen 
and colleagues (15) concluded that there is indeed a weak but sig­
nificant association between (3-agonist use and death. The corre­
lation between death from asthma and p-agonist use in 364 cases 
and 1,388 control subjects was r = 0.10, p < 0.000001 (15). How­
ever, this relationship only emerged when p-agonists were ad­
ministered with a nebulizer and not with a metered-dose inhaler. 
As administration of P-agonists with a nebulizer is normally restricted 
to the most severe cases of asthma, it seems probable that these 
asthmatics were more at risk of dying from asthma than other asth­
matic patients who could be treated with a metered-dose inhaler. 
So the severity of the disease in these patients has caused both 
the asthma-related death and the use of a p-agonist by means of 
a nebulizer. This problem of the direction of causality is inherent 
to epidemiologic studies and can only be solved by randomized 
clinical trials, in which indicators of the disease are studied under 
controlled circumstances. The significant association between death 
from asthma and p-agonist use in this meta-analysis (15) was mainly
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caused by the results of Spitzer and colleagues' study (6). This study 
differed from the others in at least one important aspect: the sub­
jects were older. It seems probable that older patients are more 
likely to rely on self-medication with bronchodilators in emergency 
situations or to deny the severity of an asthma emergency (15).
Some randomized clinical trials report that continuous use of 
bronchodilators increases bronchial hyperresponsiveness during 
or after using a P-agonist (7-9,11). However, other studies do not 
support this observation (10,16-20). If we take a closer look at the 
results of these studies, it seems that the more patients are involved, 
the less clear the adverse effect on bronchial hyperresponsiveness 
is. Almost all the studies that show increased bronchial hyperrespon­
siveness investigated fewer than 20 subjects, while studies with 
53, 91, and 113 participating subjects, respectively, did not point 
to increased bronchial hyperresponsiveness during continuous 
bronchodilator use (18,19, 10). This may imply that bronchodila­
tors only have an adverse effect in small, selected groups of asth­
matics. All the changes in hyperresponsiveness observed were be­
tween 0.5 and 1.5 doubling dose of the challenge test, which is 
virtually identical to the replicability of the test and therefore of doubt­
ful clinical significance.
We conducted a randomized study that showed that continu­
ous use of bronchodilators for 2 yr may increase the decline in 
lung function when compared to treatment on demand (10). No 
other studies comparing different forms of bronchodilator use 
lasted long enough to assess a yearly decline in lung function. 
In our study, 223 adult patients with asthma or COPD, recruited 
from 29 general practices, were randomly assigned to either con­
tinuous treatment (with 1600 |.ig salbutamol or 160 f.ig ipratropium 
bromide dally; n = 113) or treatment on demand (medication only 
during exacerbations or periods of dyspnea; n = 110). Patients 
were randomly assigned either to the group that used salbutamol 
during the first year and ipratropium during the second or to the 
group that used these drugs in reverse order (cross-over design). 
No differences in efficacy between the two drugs could be as­
sessed.
A follow-up study with 56 patients, who had a high decline in 
lung function and a high exacerbation rate during bronchodilator 
use alone in the first 2 yr, clearly showed that an inhaled cortico­
steroid could not only slow down but also partly reverse the de­
terioration of asthma or COPD (21). We also followed the remain­
ing 83 patients, who had shown to be nonsteroid-dependent in 
the first 2 yr, during another 2 yr of bronchodilator treatment alone 
(22). In these patients there was no difference at all between 4-yr 
continuous use of bronchodilators and use on demand with re­
spect to decline in lung function, bronchial hyperresponsiveness, 
mean morning peak flow, diurnal variation of peak flow, the num­
ber of exacerbations, or experienced health (23). So the deleteri­
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ous effects of continuous use of p-agonists could not be demon­
strated in these nonsteroid-dependent patients.
These observations clearly show that possible negative effects 
of bronchodilators are not as general as originally assumed (10, 
11). It seems likely that some patients with asthma (and maybe 
also patients with COPD) are more sensitive to deleterious effects 
of bronchodilators than others. It is relevant to know which pa­
tients deteriorate during continuous use of a bronchodilator alone 
and therefore need additional medication.
In order to find out whether there are subgroups of patients 
who are more sensitive than others to possible deleterious effects 
of bronchodilators, we have analyzed our original data again (10). 
We performed a multivariate analysis in which the effects of sev­
eral variables (such as atopy, smoking behavior, reversibility of 
obstruction, baseline bronchial hyperresponsiveness, baseline 
FEN/,, peak-flow variability, age, and sex) on the decline in lung 
function were investigated. We assessed the separate and com­
bined effects of these variables on the decline in lung function 
during use of salbutamol and of ipratropium in patients with asthma 
and COPD separately. We observed that only asthmatic patients 
who were both allergic (i.e., allergic to at least one out of seven 
radioallergosorbent tests to pollen from weeds, grasses, and trees; 
cats and dogs; house dust mites; and Aspergillus fumigatus) and 
had a high reversibility of obstruction (i.e., FEV, reversible more 
than 15%, 60 min after inhaling 400 ixg salbutamol and 80 ng 
ipratropium bromide, compared to the baseline) had an increased 
decline in lung function during use of the p-adrenergic drug sal­
butamol. As this effect was independent of all other important char­
acteristics (e.g., baseline bronchia! hyperresponsiveness, base­
line lung function, peak-flow variability, smoking, age, or sex), it 
seems probable that reversibility and allergy were not merely 
measures of the severity of the disease but were real determinants 
of an increased decline in lung function during bronchodilator use. 
In the Table, this is illustrated by presenting regression lines of 
the decline in lung function of several subgroups of patients who 
used salbutamol daily during 1 yr (multivariate analysis not pre­
sented). Recently, Cockcroft and colleagues observed that 2 wk 
of regular inhaled salbutamol increased airway responsiveness 
to allergen and caused tolerance to the protective effect of sal­
butamol on bronchoconstriction induced by allergen (14). They 
speculated that the enhanced airway response to allergen was 
due to enhanced mediator release from mast cells, possibly due 
to mast-cell (3-receptor downregulation. This would mean that regu­
lar use of p2-agonists in conjunction with exposure to allergens 
would induce inflammation, which in turn is an important deter­
minant of an increased decline in lung function (24). It would also 
explain why p2-agonists induce an increase in hyperresponsive­
ness in some patients (7-9, 11) and not in others (10, 16-20).
It seems paradoxical that especially allergic, reversible-ob- 
struction patients should be cautious in using p2-agonists chroni­
cally, as these patients in general will benefit most from the acute 
bronchodilating effect of these drugs. This allows a second ex­
planation for the possibly deleterious effects of bronchodilators, 
namely a masking effect of the drug (25). If a patient is sensitive 
to some antigen and wheezes or gets dyspnea on exposure, his 
natural tendency will be to stay away from it. The bronchocon- 
strictive reaction to antigen will warn him against repeated ex­
posures. If, on the other hand, the patient is given effective bron­
chodilator medication that allows him to “have a normal life,” he 
will quickly learn to get rid of the wheezing when it starts or to 
prevent it altogether by taking the bronchodilator in advance. Be­
cause the |32-agonist drug does not interfere with the late reac­
tion to the inhaled substance, patients may eventually develop 
a progressive inflammatory airway disease with increasing bron­
chial hyperresponsiveness. We observed earlier that there was 
a correlation between the decline in lung function and the increase 
in bronchial symptoms in patients who had been treated on de­
mand, but that there was no correlation at all in patients who had 
been treated with bronchodilators continuously (26). A poor per­
ception of the severity of asthma seems to be a predictor of se­
vere asthma, and it may be possible that bronchodilator drugs 
influence afferent signaling and its processing in the brain (27). 
A masking effect may be particularly important for long-acting 
bronchodilators, as these drugs are especially effective in treat­
ing symptoms and have occasionally been shown to suppress the 
subjective need for anti-inflammatory medication during chronic 
use (28). These (partly hypothetical) relationships are summarized 
in the figure.
Several international guidelines (29,30) recommend using ad­
ditional medication such as inhaled corticosteroids in case of an 
increased need for bronchodilators. If this recommendation is valid, 
it is important to know the dose of the bronchodilator inhalant at 
which deleterious effects will appear. In other words, at which dose 
is it better to use additional anti-inflammatory medication than to 
raise the dose of the bronchodilator? No studies have appeared 
on this subject thus far. In our original data (10), we therefore related 
the decline in lung function to the mean daily dose of salbutamol 
in asthmatics. Of the participating patients, 34 asthmatics used 
400 ng salbutamol between 0 and 4 times daily. We observed that 
only patients who used an average of more than 400 ng salbutamol 
daily had an increased decline in lung function. In these patients, 
there was even a correlation between the mean daily dose of sal­
butamol and the yearly decline in lung function (average decline 
in FEV( of 110 ml/yr/400 |ig salbutamol). Differences in lung func­
tion decline were not caused by differences in the severity of 
asthma at the start of the study: there were no significant differ-
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YEARLY DECLINE IN LUNG FUNCTION DURING DAILY USE OF SALBUTAMOL
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Reversibility >15%* + atopy y = -150x + 408 0.02 0.36 14
Ex/nonsmoker + reversibility >15%* y = -108x + 303 0.08 0.18 18
Ex/nonsmoker + atopy y = -101x + 220 0.14 0.15 16
Reversibility >15%* + hyperresponsivenesst y = -62x + 73 0.37 0.07 13
Ex/nonsmoker + hyperresponsivenesst y =  -61x + 73 0.37 0.07 18
Atopy + hyperresponsivenesst y = -  7x -1 8  0.93 0.03 13
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Table summarizes yearly decline of several subgroups of asthmatic patients. The change in FEVj in ml/yr (y), the mean dally dose of salbutamol 
given In increments of 400 ng (x), and the corresponding correlation coefficients are given.
* Reversibility of FEV, 60 mln after Inhaling 400 ng salbutamol and 80 jig ipratropium bromide compared to the baseline, 
t  Bronchially hyperresponsive: PC2t) < 2 mg/mi.
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Figure.
ences in lung function, bronchial hyperresponsiveness, or symp­
toms between patients who rarely needed medication and patients 
who needed medication more than once daily. These findings 
clearly confirm the advice proposed by the British Thoracic Soci­
ety (29) to use additional anti-inflammatory medication if patients 
need a bronchodilator more than once daily (e.g., salbutamol 400 
ng daily). This observation also points to the paradox already men­
tioned: patients who need bronchodilator medications most seem 
to be most sensitive to their deleterious effects.
There are indications that the incidence of asthma is still ris­
ing (31), and it is clear that the use of bronchodilators has tremen­
dously increased in the past decade (32). However, the available 
data do not provide firm evidence that the use of bronchodilators 
itself causes this increased morbidity. It seems more logical that 
the increased morbidity demands intensified therapy. There may 
be one exception: there are indications that chronic use of p2- 
agonists increases the severity of asthma in allergic patients with 
reversible obstruction. This could be explained by several under­
lying pathophysiologic mechanisms, which should be investigated. 
Patients should be carefully instructed to inform their physician 
when they need a bronchodilator more than once daily. When there 
is not undue reliance on bronchodilators, the general concern 
among patients and doctors about chronic use of these drugs does 
not seem to be justified.
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